Disease Detail

ID DOID:60079
Name Her2-receptor positive breast cancer
Definition A breast cancer that is characterized by the presence of Her2 receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer Her2-receptor positive breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA wild-type Buparlisib + Trastuzumab Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 pos PIK3CA act mut Buparlisib + Trastuzumab Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Buparlisib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PTEN loss Trastuzumab Her2-receptor positive breast cancer decreased response detail...
ERBB2 pos PIK3CA act mut Trastuzumab Her2-receptor positive breast cancer decreased response detail...
ERBB2 amp Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive MGAH22 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive MM-302 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Sunitinib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive HER2 Vaccine Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Oxaliplatin + Trastuzumab + TS-1 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Capecitabine + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Everolimus + Trastuzumab + Vinorelbine Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Oxaliplatin + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 T798M Lapatinib Her2-receptor positive breast cancer resistant detail...
ERBB2 over exp PIK3CA H1047R Trastuzumab Her2-receptor positive breast cancer resistant detail...
ERBB2 over exp PIK3CA H1047R Bevacizumab + Buparlisib Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp PIK3CA H1047R Buparlisib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp PIK3CA H1047R Lapatinib + Trastuzumab Her2-receptor positive breast cancer resistant detail...
ERBB2 over exp PIK3CA H1047R Pertuzumab + Trastuzumab Her2-receptor positive breast cancer resistant detail...
ERBB2 over exp PIK3CA H1047R Buparlisib + Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp PIK3CA H1047R Buparlisib + Lapatinib + Trastuzumab Her2-receptor positive breast cancer no benefit detail...
PIK3CA mutant CCT128930 Her2-receptor positive breast cancer sensitive detail...
FGFR1 amp Dovitinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Copanlisib Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp PIK3CA mut Copanlisib Her2-receptor positive breast cancer sensitive detail...
FGFR2 amp Dovitinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp NAX014 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Afatinib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp PIK3CA mut PKI-179 Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp CUDC-101 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Varlitinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Tucatinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp MGAH22 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 amp Palbociclib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Lapatinib + Palbociclib Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp PIK3CA E545K PIK3CA K567R Gedatolisib Her2-receptor positive breast cancer sensitive detail...
Unknown unknown BMS-906024 Her2-receptor positive breast cancer not applicable detail...
PIK3CA wild-type Lapatinib + Paclitaxel + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Ado-trastuzumab emtansine + Tucatinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Trastuzumab + Tucatinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Capecitabine + Tucatinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Capecitabine + Trastuzumab + Tucatinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 pos PTEN mut Buparlisib + Trastuzumab Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Trodusquemine Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp PF-05280014 Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA mut AT13148 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Lapatinib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA mut Lapatinib + Trastuzumab Her2-receptor positive breast cancer decreased response detail...
ERBB2 positive Ado-trastuzumab emtansine + Docetaxel Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Ado-trastuzumab emtansine + Docetaxel + Pertuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA act mut Palbociclib + Pictilisib Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PTEN loss Palbociclib + Pictilisib Her2-receptor positive breast cancer no benefit detail...
ERBB2 positive Lapatinib + MK2206 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive CDX-3379 Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp CDX-3379 Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp CDX-3379 + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp PTEN dec exp CDX-3379 Her2-receptor positive breast cancer decreased response detail...
ERBB2 pos PTEN dec exp Trastuzumab Her2-receptor positive breast cancer decreased response detail...
ERBB2 positive Entinostat + Lapatinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Entinostat + Lapatinib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive MYL-1401O + Paclitaxel Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA mut Capecitabine + Lapatinib Her2-receptor positive breast cancer decreased response detail...
ERBB2 pos PIK3CA K111N Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA I391M Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA C420R Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA H1047R Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA E545K Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Hertuzumab-vc-MMAE Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp TAK-285 Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp BGB-283 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 over exp ADXS31-164 Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Ibrutinib Her2-receptor positive breast cancer predicted - sensitive detail...
Unknown unknown Abemaciclib + Lapatinib Her2-receptor positive breast cancer not applicable detail...
Unknown unknown Abemaciclib Her2-receptor positive breast cancer not applicable detail...
Unknown unknown Abemaciclib + Trastuzumab Her2-receptor positive breast cancer not applicable detail...
ERBB2 over exp Lapatinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp PIK3CA mut Ipatasertib Her2-receptor positive breast cancer sensitive detail...
ERBB2 pos PIK3CA mut Lapatinib Her2-receptor positive breast cancer decreased response detail...
ERBB2 pos PIK3CA mut Trastuzumab Her2-receptor positive breast cancer decreased response detail...
ARID1A loss Trastuzumab Her2-receptor positive breast cancer resistant detail...
ARID1A loss AZD8055 Her2-receptor positive breast cancer resistant detail...
ERBB2 positive Neratinib + Paclitaxel Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Pyrotinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 mutant Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Metformin Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Capecitabine + Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive CT-P6 Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp KRIBB11 + MK2206 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive ZW25 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive Poziotinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive SB3 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive ABP 980 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive HER2 BATs Her2-receptor positive breast cancer sensitive detail...
Unknown unknown S63845 Her2-receptor positive breast cancer not applicable detail...
ERBB2 amp S63845 + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp Lapatinib + S63845 Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp ERBB2 L755S Lapatinib Her2-receptor positive breast cancer resistant detail...
ERBB2 L755S Lapatinib Her2-receptor positive breast cancer resistant detail...
ERBB2 amp ERBB2 L755S Lapatinib + Trastuzumab Her2-receptor positive breast cancer resistant detail...
ERBB2 amp ERBB2 L755S Pertuzumab + Trastuzumab Her2-receptor positive breast cancer resistant detail...
ERBB2 amp ERBB2 L755S Ado-trastuzumab emtansine Her2-receptor positive breast cancer decreased response detail...
ERBB2 amp ERBB2 L755S Afatinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp ERBB2 L755S Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Carboplatin + Docetaxel + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive Paclitaxel + Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 positive MEDI4276 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 over exp Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp Ado-trastuzumab emtansine Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp trastuzumab and hyaluronidase-oysk injection Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp trastuzumab and hyaluronidase-oysk injection Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp ERBB2 Y772_A775dup Neratinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 amp ERBB2 D769Y Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp ERBB2 V777L Neratinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 amp ERBB2 D769Y Trastuzumab Her2-receptor positive breast cancer resistant detail...
ERBB2 amp ERBB2 D769Y Lapatinib Her2-receptor positive breast cancer resistant detail...
ERBB2 amp ERBB2 L755S Trastuzumab Her2-receptor positive breast cancer decreased response detail...
ERBB2 amp ERBB2 R456C Neratinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 amp ERBB2 L313I Neratinib Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 positive GBR1302 Her2-receptor positive breast cancer predicted - sensitive detail...
ERBB2 amp TAS0728 Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp Trastuzumab + Vinorelbine Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp Trastuzumab + Vinorelbine Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp Lapatinib + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp Neratinib Her2-receptor positive breast cancer sensitive detail...
ERBB2 amp Docetaxel + Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
ERBB2 over exp Docetaxel + Pertuzumab + Trastuzumab Her2-receptor positive breast cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00411788 Phase II Sirolimus + Trastuzumab A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer Completed
NCT00574587 Phase Ib/II Paclitaxel + Vorinostat Trastuzumab Cyclophosphamide + Doxorubicin Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis Unknown status
NCT01016886 Phase Ib/II Bisoprolol Perindopril Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Unknown status
NCT01160211 Phase III Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Active, not recruiting
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01273610 Phase II Lapatinib + Trastuzumab Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer Active, not recruiting
NCT01276041 Phase II Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer Active, not recruiting
NCT01300962 Phase I Buparlisib + Capecitabine + Lapatinib Buparlisib + Capecitabine + Trastuzumab Buparlisib + Capecitabine Alpelisib + Capecitabine Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Active, not recruiting
NCT01305941 Phase II Everolimus + Trastuzumab + Vinorelbine A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Completed
NCT01325207 Phase Ib/II Trastuzumab Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer Completed
NCT01434303 Phase I Entinostat + Lapatinib + Trastuzumab Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only Completed
NCT01491737 Phase II Anastrozole Letrozole Trastuzumab Pertuzumab + Trastuzumab A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN) Active, not recruiting
NCT01494662 Phase II Capecitabine + Neratinib Neratinib HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Recruiting
NCT01513083 Phase I Ado-trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function Completed
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed
NCT01565083 Phase II Pertuzumab + Trastuzumab + Vinorelbine A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer Completed
NCT01566721 Phase III Trastuzumab A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer) Active, not recruiting
NCT01602406 Phase I LJM716 + Trastuzumab Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Completed
NCT01622868 Phase II Lapatinib Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Recruiting
NCT01702558 Phase II Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Capecitabine A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer Terminated
NCT01702571 Phase III Ado-trastuzumab emtansine A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment Active, not recruiting
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01772472 Phase III Ado-trastuzumab emtansine Trastuzumab A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting
NCT01783756 Phase Ib/II Capecitabine + Everolimus + Lapatinib Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis Active, not recruiting
NCT01796197 Phase II Cyclophosphamide + Doxorubicin Pertuzumab + Trastuzumab Paclitaxel Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Active, not recruiting
NCT01808573 Phase III Capecitabine + Lapatinib Capecitabine + Neratinib A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA) Active, not recruiting
NCT01816035 Phase I Ado-trastuzumab emtansine Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery Completed
NCT01828021 Phase II MGAH22 Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer Completed
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated
NCT01853748 Phase II Paclitaxel + Trastuzumab Ado-trastuzumab emtansine T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Active, not recruiting
NCT01855828 Phase II Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer Active, not recruiting
NCT01873833 Phase II Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT01875666 Phase I Lapatinib + Trastuzumab Trastuzumab Pertuzumab Pertuzumab + Trastuzumab Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Active, not recruiting
NCT01901146 Phase III Cyclophosphamide + Epirubicin Paclitaxel + Trastuzumab Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac) Completed
NCT01904903 Phase II Pertuzumab Ado-trastuzumab emtansine Trastuzumab Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt) Active, not recruiting
NCT01912963 Phase II Eribulin Pertuzumab Trastuzumab Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Terminated
NCT01921335 Phase I Trastuzumab + Tucatinib Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer Active, not recruiting
NCT01922921 Phase Ib/II HER-2/neu intracellular domain protein + Pertuzumab + Polysaccharide-K + Trastuzumab HER-2/neu intracellular domain protein + Pertuzumab + Trastuzumab Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy Active, not recruiting
NCT01924351 Phase II HER2-positive Breast Cancer With Brain Metastasis (GCC 1345) Withdrawn
NCT01934894 Phase II Cabazitaxel + Lapatinib Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases Terminated
NCT01937117 Phase II Pertuzumab + Trastuzumab Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Active, not recruiting
NCT01966471 Phase III Ado-trastuzumab emtansine + Pertuzumab Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer Active, not recruiting
NCT01976169 Phase I Ado-trastuzumab emtansine + Palbociclib Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) Recruiting
NCT01983501 Phase I Ado-trastuzumab emtansine + Tucatinib A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Active, not recruiting
NCT01989676 Phase III Paclitaxel + Trastuzumab Paclitaxel + PF-05280014 A Study Of PF-05280014 [Trastuzumab-Pfizer] Or HerceptinĀ® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) Active, not recruiting
NCT02000596 Phase II Pertuzumab + Trastuzumab Anastrozole + Fulvestrant Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC Terminated
NCT02003209 Phase III Carboplatin + Docetaxel + Goserelin + Pertuzumab + Trastuzumab Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02025192 Phase I Capecitabine + Trastuzumab + Tucatinib Trastuzumab + Tucatinib Capecitabine + Tucatinib A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Active, not recruiting
NCT02038010 Phase I Ado-trastuzumab emtansine + Alpelisib BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx Active, not recruiting
NCT02060253 Phase I Ganetespib + Paclitaxel + Trastuzumab Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Completed
NCT02061332 Phase Ib/II HER2-pulsed DC1 vaccine DC Vaccine for Patients With Ductal Carcinoma In Situ Active, not recruiting
NCT02063724 Phase I HER2-pulsed DC1 vaccine HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) Active, not recruiting
NCT02066532 Phase Ib/II Ruxolitinib + Trastuzumab Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Active, not recruiting
NCT02073487 Phase II Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel Completed
NCT02073916 Phase I Ado-trastuzumab emtansine + Lapatinib + Nab-paclitaxel TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Completed
NCT02091960 Phase II Enzalutamide + Trastuzumab A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer Active, not recruiting
NCT02131064 Phase III Ado-trastuzumab emtansine + Pertuzumab Carboplatin + Docetaxel + Pertuzumab + Trastuzumab A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer Completed
NCT02132949 Phase II Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer. Active, not recruiting
NCT02139358 Phase Ib/II Gemcitabine + Pertuzumab + Trastuzumab Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Active, not recruiting
NCT02152943 Phase I Everolimus + Letrozole + Trastuzumab Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Active, not recruiting
NCT02154529 Phase Ib/II Trastuzumab + XL647 Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Terminated
NCT02167854 Phase I Alpelisib + LJM716 + Trastuzumab Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer Active, not recruiting
NCT02187744 Phase III Carboplatin + Docetaxel + Trastuzumab A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) Completed
NCT02213042 Phase II Lapatinib + Trastuzumab Trastuzumab Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT02213744 Phase II Trastuzumab + Vinorelbine Capecitabine + Trastuzumab Gemcitabine + Trastuzumab MM-302 + Trastuzumab MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients Terminated
NCT02229149 Phase II Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer Active, not recruiting
NCT02236000 Phase Ib/II Ado-trastuzumab emtansine + Neratinib A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer Recruiting
NCT02252887 Phase II Gemcitabine + Pertuzumab + Trastuzumab Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab Active, not recruiting
NCT02297230 Phase Ib/II Capecitabine Paclitaxel Paclitaxel + Trastuzumab Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics Terminated
NCT02297698 Phase II Sargramostim Trastuzumab E75 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients Active, not recruiting
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Active, not recruiting
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT02326974 Phase II Ado-trastuzumab emtansine + Pertuzumab T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA Active, not recruiting
NCT02336984 Phase Ib/II Trastuzumab HER2-pulsed DC1 vaccine A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS Active, not recruiting
NCT02345772 Phase I Fulvestrant Docetaxel + Pertuzumab + Trastuzumab Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer Terminated
NCT02390427 Phase I Trastuzumab Paclitaxel Pertuzumab Taselisib Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer Recruiting
NCT02400476 Phase II Neratinib A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide Recruiting
NCT02402712 Phase III Docetaxel + Pertuzumab + Trastuzumab Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer Completed
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed
NCT02414646 Phase II Trastuzumab dy Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer Active, not recruiting
NCT02492711 Phase III Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin MGAH22 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Active, not recruiting
NCT02500199 Phase I Pyrotinib Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy Recruiting
NCT02536339 Phase II Pertuzumab + Trastuzumab Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy Active, not recruiting
NCT02571530 Phase I Trastuzumab Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer Recruiting
NCT02598427 Phase I Pertuzumab + Trastuzumab Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer Terminated
NCT02605915 Phase I Atezolizumab + Trastuzumab Docetaxel Carboplatin Pertuzumab Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer Active, not recruiting
NCT02614794 Phase II Capecitabine + Trastuzumab + Tucatinib Capecitabine + Trastuzumab Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer Active, not recruiting
NCT02649686 Phase I Durvalumab + Trastuzumab Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab Active, not recruiting
NCT02650752 Phase I Capecitabine + Lapatinib Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases Active, not recruiting
NCT02654119 Phase II Cyclophosphamide + Paclitaxel + Trastuzumab Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery Recruiting
NCT02657343 Phase Ib/II Ribociclib Trastuzumab Ado-trastuzumab emtansine An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Active, not recruiting
NCT02658084 Phase Ib/II Ado-trastuzumab emtansine + Vinorelbine Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer Terminated
NCT02659514 Phase II Poziotinib Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer Active, not recruiting
NCT02675231 Phase II Trastuzumab Abemaciclib + Trastuzumab Abemaciclib + Fulvestrant + Trastuzumab A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER) Active, not recruiting
NCT02689921 Phase II Anastrozole Letrozole Leuprolide Pertuzumab + Trastuzumab Exemestane NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT) Active, not recruiting
NCT02774681 Phase II Trastuzumab Palbociclib Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis Active, not recruiting
NCT02789657 Phase II Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. Recruiting
NCT02827877 Phase I Pertuzumab + Trastuzumab Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer Recruiting
NCT02892123 Phase I Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 Trial of ZW25 in Patients With Advanced HER2-expressing Cancers Recruiting
NCT02907918 Phase II Goserelin Letrozole + Palbociclib + Trastuzumab Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN) Recruiting
NCT02924883 Phase II Trastuzumab Atezolizumab + Trastuzumab A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2) Active, not recruiting
NCT02947685 Phase III Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Trastuzumab Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) Recruiting
NCT03054363 Phase Ib/II Letrozole + Palbociclib + Tucatinib Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer Recruiting
NCT03112590 Phase Ib/II interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Recruiting
NCT03125928 Phase II Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer Recruiting
NCT03135171 Phase I Pertuzumab + Tocilizumab + Trastuzumab Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab Recruiting
NCT03155997 Phase III Abemaciclib Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Active, not recruiting
NCT03190967 Phase Ib/II Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Temozolomide T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery Recruiting
NCT03284723 Phase I PF-06804103 PF-06804103 Dose Escalation in HER2 Positive Solid Tumors Recruiting
NCT03304080 Phase Ib/II Anastrozole + Palbociclib + Pertuzumab + Trastuzumab Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast Recruiting
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Recruiting
NCT03321981 Phase II Letrozole + MCLA-128 Anastrozole + MCLA-128 Fulvestrant + MCLA-128 Exemestane + MCLA-128 MCLA-128 + Trastuzumab MCLA-128 + Trastuzumab + Vinorelbine MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer Recruiting
NCT03329378 Phase II Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer Recruiting
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Recruiting
NCT03364348 Phase I Trastuzumab + Utomilumab Ado-trastuzumab emtansine + Utomilumab 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Recruiting
NCT03368729 Phase Ib/II Niraparib + Trastuzumab Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Not yet recruiting
NCT03377387 Phase Ib/II Capecitabine + Neratinib Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Recruiting
NCT03379428 Phase Ib/II Trastuzumab Ibrutinib + Trastuzumab Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Recruiting
NCT03387553 Phase I HER2-pulsed DC1 vaccine HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer Recruiting
NCT03414658 Phase II Avelumab + Trastuzumab + Utomilumab + Vinorelbine Avelumab + Trastuzumab + Vinorelbine Avelumab + Trastuzumab + Utomilumab Trastuzumab + Vinorelbine The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Recruiting
NCT03417544 Phase II Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Recruiting
NCT03429101 Phase I Ado-trastuzumab emtansine + Poziotinib A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer Active, not recruiting
NCT03433313 Phase III Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer Recruiting
NCT03451162 Phase I DHES0815A Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer Recruiting
NCT03493854 Phase III Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Active, not recruiting
NCT03501979 Phase II Capecitabine + Trastuzumab + Tucatinib Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD Recruiting
NCT03521245 Phase I Trastuzumab Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer Recruiting
NCT03523585 Phase III DS-8201a Capecitabine + Lapatinib Capecitabine + Trastuzumab DS-8201a Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care Recruiting
NCT03529110 Phase III DS-8201a Ado-trastuzumab emtansine DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Recruiting
NCT03530696 Phase II Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Palbociclib T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1) Recruiting
NCT03587740 Phase II Ado-trastuzumab emtansine ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer Recruiting
NCT03620201 Phase I M7824 M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC) Recruiting
NCT03674112 Phase II Pertuzumab + Trastuzumab A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer Recruiting
NCT03709082 Phase Ib/II Ado-trastuzumab emtansine + Letrozole + Palbociclib Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Recruiting
NCT03716180 Phase I Paclitaxel + Pertuzumab + Trastuzumab DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC Recruiting
NCT03726879 Phase III Cyclophosphamide + Doxorubicin Atezolizumab + Cyclophosphamide + Doxorubicin Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) Recruiting
NCT03747120 Phase II Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab Recruiting
NCT03765983 Phase II GDC-0084 + Trastuzumab GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases Recruiting
NCT03846583 Phase I Abemaciclib + Trastuzumab + Tucatinib Tucatinib + Abemaciclib + Herceptin for HER2+ MBC Not yet recruiting
NCT03983395 Phase Ib/II GBR1302 Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer Not yet recruiting